The funding will allow 52North to move its products, including its Neutrocheck point-of-care device, toward commercialization.

The TarCET Kit offers a suite of sequencing panels covering a range of genetic conditions including metabolic disorders, infertility, and cardiovascular diseases.

Out of the 30 companies tracked by 360Dx, 13 saw their share prices increase, while 17 saw their stock prices decline.

The awards will support the development of US Food and Drug Administration-cleared tests for Marburg virus and Burkholderia pseudomallei infection.

Last week, readers were most interested in a story about Agilent changing two of its three business organizations to accelerate growth.